Robert Hofmeister, Chief Science Officer at TCR2 THERAPEUTICS INC. (TCRR), sold 20,000 shares at $19.10 ($382K) on 2020-10-29, disclosed to the SEC on 2020-11-02.
Open-market sale of $382k TCRR by Chief Science Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.